ReviewPatient preference and adherence2013
Factors involved in patient choice of oral or vaginal treatment for vulvovaginal candidiasis.
Review in Patient preference and adherence, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Treatment for recurrent vulvovaginal candidiasis (thrush).The Cochrane database of systematic reviews · 2022Pooled it
- Limosilactobacillus fermentum 21 N1 Mitigates Candida albicans-Induced Vulvovaginal Candidiasis and Suppresses NLRP3 Inflammasome Activation in a Mouse Model.Probiotics and antimicrobial proteins · 2026Article
- Novel Drug Delivery Systems for the Management of Vulvovaginal Candidiasis: Enhancing Therapeutic Efficacy.Current pharmaceutical design · 2026Review
- Assessment of patient perception and administration technique of vaginal tablets at a tertiary care women's hospital.Exploratory research in clinical and social pharmacy · 2025Article
- Knowledge of Vulvovaginal Candidiasis Characteristics, Signs, Symptoms, and Appropriate Treatment Among Portuguese Pharmacy Professionals.Healthcare (Basel, Switzerland) · 2025Article
- Protective Properties of S-layer Protein 2 fromBiomolecules · 2023Article
- Barriers and facilitators of adherence to treatment among women with vulvovaginal candidiasis: a qualitative study.European journal of medical research · 2022Article
- Vulvovaginal candidiasis: A real-world evidence study of the perceived benefits of CanestenSAGE open medicine · 2022Article
- Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis.SAGE open medicine · 2022Review
- The Role of Fatty Acid Metabolites in Vaginal Health and Disease: Application to Candidiasis.Frontiers in microbiology · 2021Review
- Treatment of vulvovaginitis.Australian prescriber · 2020Review
- Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study.BMJ (Clinical research ed.) · 2020Article
- Vulvovaginal Candidiasis: A Current Understanding and Burning Questions.Journal of fungi (Basel, Switzerland) · 2020Review
- Preclinical approaches in vulvovaginal candidiasis treatment with mucoadhesive thermoresponsive systems containing propolis.PloS one · 2020Article
- Vaginal lactobacilli inhibit growth and hyphae formation of Candida albicans.Scientific reports · 2019Article
- Article
- ERG2 and ERG24 Are Required for Normal Vacuolar Physiology as Well as Candida albicans Pathogenicity in a Murine Model of Disseminated but Not Vaginal Candidiasis.Eukaryotic cell · 2015Article
- What do portuguese women prefer regarding vaginal products? Results from a cross-sectional web-based survey.Pharmaceutics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vulvovaginal candidiasis (VVC) is an extremely common cause of vaginal symptoms in women. Multiple antifungal products are available by either the oral or vaginal route, although no new drugs have become available for two decades. Given the therapeutic equivalence of the antimycotic agents and their routes of administration, the specific drug and formulation selected is entirely arbitrary in relation to final treatment outcome. Nevertheless, multiple factors affecting preference, both practitioner-dependent and patient-dependent, impact on selection of a specific drug and route of administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.